Neurometa Therapeutics

Private

LundHealthcare & Life Scienceshttps://neurometa.com/

Last Round

Accelerator

May 21, 2025

Total Funding Raised

$2.46M

Company Overview

Neurometa Therapeutics is a biotechnology company developing a novel neurometabolic approach to treating neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Application

Keywords

neurodegenerative disease therapeuticssmall molecule drugsneurometabolismdisease-modifying therapiesbiotechfirst-in-class therapeuticsALS treatmentpreclinical biotechdrug discovery platformParkinson's disease treatmentmultiple sclerosis treatmentneuronal metabolismpharma partnershipsAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neurometa Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Neurometa Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Neurometa Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Accelerator	May 21, 2025
Grant	Dec 10, 2022
Seed	Sep 22, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

Steinunn Sara Helgudóttir

Chief Scientific Officer, Co-Founder & Head of Biology

Founding Team

John Dirk Vestergaard Nieland

CIO, COO consultant

Executive Team

Neurometa Therapeutics Investors

Notable investors and investment history

Neurometa Therapeutics investors
Investor	Rounds
U.S. Department of War	Grant
BioInnovation Institute	Seed
SmiLe Venture Hub	Accelerator

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Nov 14, 2025
Grew 60% QoQ, from 10 to 16 employees.
Apr 16, 2024
Grew 38% QoQ, from 8 to 11 employees.

View all signals

Neurometa Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Neurometa Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Neurometa Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLund

Employee Range15

Year Founded2019

Last FundingMay 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.